BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

MoonLake Immunotherapeutics (MLTX)MoonLake Immunotherapeutics2026-06-25 13:46 ESTFinancing

ZUG, Switzerland , November 5, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced the pricing of an underwritten offering of

Open original release

Related news

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

View all latest news

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.

Recent company news

MLTXMoonLake Immunotherapeutics2026-06-26 08:21 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-26 08:21 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-26 08:21 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-06-26 08:21 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-26 08:21 EST

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States